# BeiGene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beigene

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.beigene.com
- Total disclosed funding: $75M
- Latest round: Series A (Nov 1, 2014)
- Investors on record: 4

## About

Established in 2010 and based in Massachusetts, US, BeiGene Ltd. is a biotechnology company that focuses on the research and development of innovative drugs. The company was listed on the NASDAQ Stock Exchange in February 2016, on the Hongkong Stock Exchange in August 2018 and on the Shanghai Stock Exchange in December 2021. Its stock code listed on the Shanghai Stock Exchange is 688235. 

The company's products include BRUKINSA, Baizean, Baihuize, and etc. The Company had 48 commercialized products and clinical-stage drug candidates, including 10 commercial-stage drugs, two filed drug candidates and 36 clinical-stage drug candidates.

## Funding rounds

- Series A, Nov 1, 2014, $75M — CPE Funds Management, Baker Brothers Advisors, Merck & Co., Inc., Hillhouse Investment

## Investors

- CPE Funds Management (https://capitalatlas.ai/funds/cpe-funds-management) — Series A
- Baker Brothers Advisors (https://capitalatlas.ai/funds/baker-brothers-advisors) — Series A
- Merck & Co., Inc. — Series A
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series A